Breakthroughs in Cancer Treatment Yield Record-Breaking Sales for Soleno Therapeutics

Soleno Therapeutics, Inc., a leading biopharmaceutical company, reported its fourth-quarter earnings call results yesterday, marking a significant milestone in the company’s quest to revolutionize cancer treatment. The Q4 2025 earnings call revealed that the company’s flagship product, Selginusab, has achieved unprecedented commercial success. According to Soleno Therapeutics’ CEO, “We are thrilled with the exceptional performance of Selginusab in Q4 2025, which demonstrates the significant impact our novel therapeutic approach is having on patients worldwide.” The milestone sales figures indicate a substantial increase in revenue from the previous quarter, surpassing expectations and cementing Selginusab’s position as a top-performing cancer treatment. Soleno Therapeutics’ Q4 2025 earnings call also highlighted key operational achievements. The company reported a significant expansion of its clinical trial program, with multiple new trials initiated to further validate Selginusab’s efficacy in various types of cancer. Additionally, Soleno announced major investments in its manufacturing capabilities, ensuring the sustained supply of Selginusab and positioning the company for future growth. The Q4 2025 earnings call marked a pivotal moment for Soleno Therapeutics, demonstrating the company’s commitment to advancing cancer treatment options. As the company continues to build on this momentum, investors are eagerly anticipating further developments in Selginusab and the broader portfolio of treatments under development by Soleno Therapeutics.